1. [The efficacy of neoadjuvant chemotherapy with S-1/CDDP (SP) to the patients with large type 3 and type 4 gastric cancer].
- Author
-
Katayanagi S, Nomura T, Sumi T, Suda T, Hoshino S, Ito K, Takagi Y, Tsuchida A, Kawachi S, and Shimazu M
- Subjects
- Aged, Cisplatin adverse effects, Drug Combinations, Female, Gastrectomy, Humans, Male, Middle Aged, Neoplasm Staging, Oxonic Acid administration & dosage, Prognosis, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoadjuvant Therapy, Stomach Neoplasms drug therapy
- Abstract
Here, I examined the efficacy of neoadjuvant chemotherapy( NAC) with S-1/CDDP( SP) in my hospital. The subjects were 8 patients with advanced gastric cancer who had undergone NAC since 2007 (7 men and 1 woman; median age, 70 years). The staging before the treatment was Stage II A: 1 patient, II B: 2 patients, III B: 3 patients, III C: 1 patient, and IV: 1 patient. The macroscopic type of 3 and 5 patients was large type 3 and type 4, respectively. Gastrectomy was performed following the NAC with SP. The NAC response rate was 62.5%. In the histological response criteria, 1 patient was grade 0, 2 patients were grade 1a, 2 patients were grade 1b, and 3 patients were grade 2. Adverse events following the NAC were in the acceptable range. We noted that the presence of Stage IV or grade 0 histological response criteria to NAC indicated poor prognosis. Thus, I believe that preoperative surgery after NAC in Stage III gastric cancer should be considered to be curative.
- Published
- 2013